Hudson Bay Capital Management
RGLS

Hudson Bay Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Hudson Bay Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-249,940
Closed -$446K – 1011
2024
Q2 		$446K Sell
249,940
-375,060
-60% -$870K ﹤0.01% 646
2024
Q1 		$1.68M Buy
+625,000
New +$1.02M 0.01% 484

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Hudson Bay Capital Management's RGLS Position: Q3 2024 in Review

Hudson Bay Capital Management sold out of Regulus Therapeutics (RGLS) in Q3 2024, closing a stake of 249,940 shares — an estimated $446K sold.

Hudson Bay Capital Management first reported a position in RGLS in Q1 2024 and held it in 2 quarters. The position peaked at $1.68M in Q1 2024. 70 funds tracked by Wall St. Rank hold RGLS as of Q3 2024.

  • Hudson Bay Capital Management reported no remaining Regulus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 249,940 Regulus Therapeutics shares in Q3 2024, an estimated $446K.
  • Hudson Bay Capital Management first reported a position in Regulus Therapeutics in Q1 2024 and held it in 2 quarters.
  • Hudson Bay Capital Management's Regulus Therapeutics position peaked at $1.68M in Q1 2024.
  • 70 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2024.

Based on Hudson Bay Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.